Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

Conventional radiation treatment might slow their growth, but Carter was certain to die. Then his doctors gave him pembrolizumab (Keytruda), a new immunotherapy medication that could spur a patient’s ...

In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of ...

Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA ...

The findings, published in The Lancet, establish pembrolizumab as a new option for patients with this disease. "Soft tissue ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (Keytruda) in the KeyVibe programme. Favezelimab is being evaluated as an investigational fixed-dose ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...